Abbvie (ABBV) stock is gaining considerable interest from investors as evident from the recent trade activity, with many investment entities acquiring, increasing, or reducing their stakes in it. The valuation of the pharma giant has attracted attention after securing a key revenue driver with Rinvoq exclusivity extension. The company's stock broke out as Rinvoq, its key revenue generating drug, lives to fight another day. The company managed to settle with generic drugmakers over Rinvoq, delaying the generics until 2037. This move has resulted in the shares of AbbVie reaching a record high. AbbVie's advancement in cancer treatments through Epcoritamab and Mirvetuximab approvals has also been a notable development. In addition to its pharmaceutical endeavors, AbbVie has entered the mental health market by acquiring psychedelic drug developer, Gilgamesh for $1.2B. On the financial front, BMO Capital Markets and Wells Fargo & Company have set new, higher price targets for ABBV. The company also declared a quarterly dividend of US$1.64 for shareholders. The company's stock has shown significant resilience even when the overall market is experiencing gains.
Abbvie ABBV News Analytics from Tue, 05 Aug 2025 07:00:00 GMT to Sat, 13 Sep 2025 23:16:14 GMT -
Rating 9
- Innovation 7
- Information 8
- Rumor 2
